Literature DB >> 2682692

Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.

J Schöpf1, P Baumann, T Lemarchand, M Rey.   

Abstract

The therapeutic efficacy of lithium added to tricyclic antidepressants (TCA) or related thymoleptics was investigated in 27 endogenous depressive patients responding unsatisfactorily to these drugs alone. All patients received lithium during two weeks, however, with a delay of one week in 13 of them, the attribution to active treatment or placebo for the first seven days being double-blind. A statistically significant improvement compared to placebo occurred after lithium addition. The results of the double-blind part of the study as well as the observations during the total two-week period suggest that endogenous depression failing to respond to thymoleptic drug treatment can be improved within a short time by the co-administration of the two treatments in the indicated sequence. However, the proportion of patients improved and the rapidity of improvement noted in this study were less favorable than reported by the investigators who discovered the therapeutic principle.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682692     DOI: 10.1055/s-2007-1014603

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

Review 1.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

Review 2.  Refractory depression: treatment strategies, with particular reference to the thyroid axis.

Authors:  R T Joffe
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

Review 3.  Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.

Authors:  Nicolas A Nuñez; Boney Joseph; Mehak Pahwa; Rakesh Kumar; Manuel Gardea Resendez; Larry J Prokop; Marin Veldic; Ashok Seshadri; Joanna M Biernacka; Mark A Frye; Zhen Wang; Balwinder Singh
Journal:  J Affect Disord       Date:  2022-01-02       Impact factor: 6.533

Review 4.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 5.  Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.

Authors:  Chia-Ming Chang; Soichiro Sato; Changsu Han
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

Review 6.  [Twenty-five years of lithium augmentation].

Authors:  T Bschor; U Lewitzka; A Pfennig; M Bauer
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 7.  Role of lithium augmentation in the management of major depressive disorder.

Authors:  Michael Bauer; Mazda Adli; Roland Ricken; Emanuel Severus; Maximilian Pilhatsch
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

8.  Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.

Authors:  Gustavo H Vázquez; Anees Bahji; Juan Undurraga; Leonardo Tondo; Ross J Baldessarini
Journal:  J Psychopharmacol       Date:  2021-07-09       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.